During the past decade, CPQuali Pesquisa Clínica Sao Paulo conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "CPQuali Pesquisa Clínica Sao Paulo" #1 collaborator was "Atea Pharmaceuticals, Inc." with 1 trials as a collaborator and "PPD" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "CPQuali Pesquisa Clínica Sao Paulo" are "COVID-19" (1 trials) and "Relapsing-Remitting Multiple Sclerosis" (1 trials). Many other conditions were trialed in "CPQuali Pesquisa Clínica Sao Paulo" in a lesser frequency.

Most popular intervention types in "CPQuali Pesquisa Clínica Sao Paulo" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Fingolimod" (1 trials), "Fingolimod Placebo" (1 trials), "Ocrelizumab" (1 trials), "Ocrelizumab Placebo" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "CPQuali Pesquisa Clínica Sao Paulo" are 2 trials for "All" genders.

Currently, there are NaN active trials in "CPQuali Pesquisa Clínica Sao Paulo". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in CPQuali Pesquisa Clínica Sao Paulo, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in CPQuali Pesquisa Clínica Sao Paulo, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".